MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Fate Therapeutics Company Profile (NASDAQ:FATE)

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (311.76% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016BMO Capital MarketsReiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Leerink SwannReiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016HC WainwrightReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015WedbushReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Raymond JamesInitiated CoverageOutperform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.27)($0.26)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.30)($0.24)$1.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.39)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.37)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.29)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.37)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.31)($0.27)($0.29)
Q2 20162($0.35)($0.33)($0.34)
Q3 20163($0.36)($0.33)($0.35)
Q4 20163($0.36)($0.24)($0.31)
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)
Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
DateHeadline
06/30/16 04:14 PMFate Therapeutics, Inc. - Product Pipeline Review - 2016 - New Market Research Report
06/30/16 05:56 AMWatching Stock Volatility for: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/28/16 03:55 PMCovering the Bases on Fate Therapeutics, Inc. (NASDAQ:FATE): Where is the Stock Going? - Press Telegraph
06/28/16 03:55 PMCheck on Share Volatility: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/27/16 03:54 PMStock Volatility in Review: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/27/16 08:26 AMFate Therapeutics Incorporated (NASDAQ:FATE) Short Interest Decreased By 8.49% - Press Telegraph
06/27/16 08:26 AMNext Weeks Broker Price Targets For Fate Therapeutics, Inc. (FATE) - Fiscal Standard
06/27/16 08:26 AMLarge Outflow of Money Witnessed in Fate Therapeutics - Trade Calls
06/24/16 04:01 PMAre Analysts Bullish Fate Therapeutics Inc (NASDAQ:FATE) After Last Week? - Engelwood Daily
06/22/16 04:06 PMFate Therapeutics (NASDAQ:FATE) Analyst Rating Consensus - TheFounders Daily
06/21/16 03:45 PMUS FDA grants fast track designation to Fate Therapeutics' ProTmune
06/21/16 03:45 PMFate Therapeutics (FATE) Boosted with FDA Fast-Track Designation
06/21/16 08:37 AMLpath, Inc. (NASDAQ:LPTN) & Fate Therapeutics (NASDAQ:FATE) Healthcare Investor's Alert - Wall Street 24
06/21/16 08:37 AMHC Stocks in Top Row: Perrigo Company plc (NYSE:PRGO), Fate Therapeutics Inc (NASDAQ:FATE) - share market updates (press release)
06/21/16 08:37 AMWhy muscled up? - Lpath, Inc. (NASDAQ:LPTN), Fate Therapeutics Inc (NASDAQ:FATE), Macrocure Ltd (NASDAQ ... - Street Register
06/21/16 07:25 AMFate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1% -
06/20/16 03:49 PMFate Therapeutics destined to rise after FDA fast-track
06/20/16 03:49 PMFate Therapeutics Announces FDA Fast Track Designation for ProTmune™
06/20/16 12:22 PM10 Biggest Mid-Day Gainers For Monday -   Lpath, Inc. (NASDAQ: LPTN) shares jumped 58.17 percent to $3.29 as the company reported that it has been awarded a $1.45 million 2-year grant for traumatic brain injury pain study. Fate Therapeutics Inc (NASDAQ: FATE) gained 19.90 percent to $2.01 as the company reported the FDA Fast Track designation for ProTmune. Neovasc Inc (US) (NASDAQ: NVCN) shares surged 17.66 percent to $0.900 as the company reported that positive results for Reducer system treatment for refractory angina were published in The Netherlands Heart Journal. Cerus Corporation (NASDAQ: Full story available on Benzinga.com
06/20/16 10:09 AMFate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International ... - PharmiWeb.com (press release)
06/20/16 10:09 AMBRIEF-Fate Therapeutics announces FDA fast track designation for Protmune - Reuters
06/20/16 07:52 AM12 Stocks Moving In Monday's Pre-Market Session - Gainers Neovasc Inc (US) (NASDAQ: NVCN) shares rose 33.35 percent to $1.020 in pre-market trading as the company reported that positive results for Reducer system treatment for refractory angina were published in The Netherlands Heart Journal. Fate Therapeutics Inc (NASDAQ: FATE) rose 27.98 percent to $2.15 in pre-market trading as the company reported the FDA Fast Track designation for ProTmune. Cerus Corporation (NASDAQ: CERS) shares rose 13.16 percent to $6.45 in pre-market trading as the company announced an agreement Sunday with the BARDA for potential funding of up to $180 million to advance INTERCEPT red blood cell program. Clean Energy Fuels Corp (NASDAQ: CLNE) rose 9.01 ...Full story available on Benzinga.com
06/20/16 07:40 AMCould This Be a Turning Point for Fate Therapeutics? -
06/16/16 07:01 AMFate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research - [GlobeNewswire] - SAN DIEGO, June 16, 2016-- Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that ...
06/15/16 04:02 PMRecently Issued Stock Ratings For Fate Therapeutics, Inc. (FATE) - Fiscal Standard
06/14/16 08:47 AMNASDAQ Gainers: Fate Therapeutics, Inc. (NASDAQ:FATE), Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), Vuzix ... - KC Register
06/11/16 09:23 PMFate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases - GlobeNewswire (press release)
06/11/16 04:00 PMFate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases - Stockhouse
06/11/16 10:01 AMFate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases - [GlobeNewswire] - One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model. ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent ...
06/08/16 04:09 PMFate Therapeutics, Inc. (FATE) Updated Price Targets - FTSE News
06/03/16 10:08 PMBroker Watchlist: Fate Therapeutics, Inc. (FATE) - Share Trading News
06/02/16 10:03 PMStock Review and Earnings Check on Fate Therapeutics, Inc. (NASDAQ:FATE) - HNN - Stock Review and Earnings Check on Fate Therapeutics, Inc. (NASDAQ:FATE)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Fate Therapeutics, Inc.and more »
05/30/16 08:53 PMPerformance at a Glance on Fate Therapeutics, Inc. (NASDAQ:FATE) - HNN - Performance at a Glance on Fate Therapeutics, Inc. (NASDAQ:FATE)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Fate Therapeutics, Inc. (NASDAQ:FATE)'s stock has performed at various points in its past. Currently ...and more »
05/30/16 08:53 PMFate Therapeutics, Inc. (FATE) Broker Price Targets For The Coming Week - Share Trading News - Fate Therapeutics, Inc. (FATE) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Fate Therapeutics, Inc. (FATE). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/25/16 01:19 PMFate Therapeutics Incorporated (NASDAQ:FATE) Sellers Covered 22.86% of Their Shorts - Wall Street Hints and News - Fate Therapeutics Incorporated (NASDAQ:FATE) Sellers Covered 22.86% of Their ShortsWall Street Hints and NewsFate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $48.02 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative ...
05/24/16 01:44 PMFate Therapeutics, Inc. (NASDAQ:FATE) Reports Basic Consolidated EPS At $-1.1769 - Investor Newswire - Fate Therapeutics, Inc. (NASDAQ:FATE) Reports Basic Consolidated EPS At $-1.1769Investor NewswireFrom the parent firm, Fate Therapeutics, Inc. (NASDAQ:FATE) diluted EPS came at $-1.1769 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $-1.1769. Fate Therapeutics, Inc. (NASDAQ:FATE) posted net basic EPS of $-1.27 for the ...
05/24/16 01:44 PMAlpha One Assigns Impact Score Of 0 To Fate Therapeutics, Inc. (NASDAQ:FATE) - RealistInvestor.com - Alpha One Assigns Impact Score Of 0 To Fate Therapeutics, Inc. (NASDAQ:FATE)RealistInvestor.comAlpha One analyzed the various web articles published on Fate Therapeutics, Inc. (NASDAQ:FATE), and thereafter it gave company a daily sentiment score of 0.56. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/18/16 01:49 PMBroker Outlook For Fate Therapeutics, Inc. (FATE) - Share Trading News - Broker Outlook For Fate Therapeutics, Inc. (FATE)Share Trading NewsFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of ...
05/18/16 01:49 PMFate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer ... - Clinical Leader - Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer ...Clinical LeaderSan Diego, CA (GLOBE NEWSWIRE) - Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the presentation of its ...
05/18/16 01:49 PMForm 3 FATE THERAPEUTICS INC For: May 16 Filed by: Storgard Chris - StreetInsider.com - Form 3 FATE THERAPEUTICS INC For: May 16 Filed by: Storgard ChrisStreetInsider.comNews and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. FORM 3, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. INITIAL STATEMENT OF ...and more »
05/17/16 02:02 PMFate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer ... - GlobeNewswire (press release) - Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer ...GlobeNewswire (press release)SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the ...Fate Therapeutics Reports Positive Data from Studies of Therapy to Kill Tumors; Shares Flat in Pre Market (NASDAQ ...Sonoran Weekly Reviewall 2 news articles »
05/17/16 02:02 PMBRIEF-Fate Therapeutics appoints Chris Storgard as chief medical officer - Reuters - BRIEF-Fate Therapeutics appoints Chris Storgard as chief medical officerReutersBRIEF-Fate Therapeutics appoints Chris Storgard as chief medical officer. May 17 Fate Therapeutics Inc. * Fate Therapeutics appoints Chris Storgard as chief medical officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: ...
05/17/16 02:02 PMFate Therapeutics (FATE) Names New Chief Medical Officer - StreetInsider.com - Fate Therapeutics (FATE) Names New Chief Medical OfficerStreetInsider.comFate Therapeutics, Inc. (Nasdaq: FATE) announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through ...Fate Therapeutics Hires Chris Storgard to Become Chief Medical Officer (NASDAQ:FATE)Sonoran Weekly ReviewHealth Care Sector Update for 05/17/2016: FATE, ABEONasdaqall 10 news articles »
05/17/16 07:01 AM8:01 am Fate Therapeutics appoints Chris Storgard Chief Medical Officer, effective immediately -
05/17/16 07:01 AMFate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer - [GlobeNewswire] - SAN DIEGO, May 17, 2016-- Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that ...
05/16/16 07:01 AMFate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy - [GlobeNewswire] - Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota. Program to be Presented Today at Innate Killer Summit 2016. SAN DIEGO, May 16, 2016-- ...
05/15/16 07:24 AMBuy Recommendations Count For Fate Therapeutics, Inc. (NASDAQ:FATE) At 1 - RealistInvestor.com - Buy Recommendations Count For Fate Therapeutics, Inc. (NASDAQ:FATE) At 1RealistInvestor.comZacks rating methodology assigns scores to companies on a simplified 1-5 scale. A score towards the 1-2 band indicates a Buy call, 3 score implies a Hold while a rating of 4 or 5 denotes Sell call. Each brokerage group has its own way of assigning ...and more »
05/14/16 07:22 AMForm 4 FATE THERAPEUTICS INC For: May 11 Filed by: Enyedy Mark J - StreetInsider.com - Form 4 FATE THERAPEUTICS INC For: May 11 Filed by: Enyedy Mark JStreetInsider.comCheck this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. Enyedy Mark J. (Last), (First), (Middle). C/O FATE THERAPEUTICS, INC.;. 3535 GENERAL ...and more »
05/09/16 03:41 PMFATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
04/11/16 07:15 AMFate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher -
About Fate Therapeutics

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company's development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)), which targets Hematologic, Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II, Phase Ib and Phase Ib, respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB), which is for Hematologic and Malignancies therapeutic area, and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells, human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FATE
  • CUSIP:
Key Metrics:
  • Previous Close: $1.70
  • 50 Day Moving Average: $1.67
  • 200 Day Moving Average: $2.08
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $49.07M
  • Current Quarter EPS Consensus Estimate: $-1.25 EPS
Additional Links:
Fate Therapeutics (NASDAQ:FATE) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha